ClinicalTrials.Veeva

Menu

Comparison of Alfredson and Silbernagel Protocol in Competitive Athletes With Achilles Tendinopathy

C

Charles University, Czech Republic

Status

Active, not recruiting

Conditions

Pain, Chronic
Achilles Tendinopathy
Tendon Thickening
Tendon Injuries

Treatments

Other: Alfredson protocol
Other: Silbernagel protocol

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

A 6-week randomized clinical trial (RCT) with a 46-week follow-up compared the effect of Alfredson and Silbernagel eccentric programs for the treatment of AT. The primary outcome was a change in the Victorian Institute of Sport Assessment - Achilles (VISA-A) scale from baseline to 12 months. The study was approved by the Ethics Committee of the Faculty of Physical Education and Sport, Charles University (Project number: 254/2021). All participants provided written informed consent before participation.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Athletes performing track and field, tennis or football at the competitive level
  • Age 18 to 40 years
  • Unilateral Achilles tendinopathy
  • Pain lasting more than 2 months
  • Diagnosis of Achilles tendinopathy established by pain on function at the Achilles region and ultrasound assessment (tendon thickening, swollen tendon) by one researcher
  • Participants trained at least 3 times per week before the onset of Achilles tendinopathy
  • Less than 3 months without training and less than 6 months from the last competition/match
  • Wish to return to original sport level
  • Willing to stop with other treatments 2 weeks before the start of the clinical trial

Exclusion criteria

  • Achilles tendon rupture in past
  • Corticosteroid injection in Achilles tendon region in last 6 months
  • Having other lower limb musculoskeletal injuries or surgery in the last 6 months (e.g., muscle rupture, bone fracture)
  • Having a neurological, systemic or autoimmune disease (e.g., neuropathy, type 1 diabetes, rheumatoid arthritis)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

40 participants in 2 patient groups

Alfredson group (A)
Active Comparator group
Description:
Participants allocated to the Alfredson exercise program were instructed to exercise twice a day on both legs for 12 months. They performed concentric calf rises (CR) on both legs up and eccentric CR on one leg down. The protocol contained 15 repetitions and 3 sets on each leg with extended and flexed knee. One session contained 45 reps in the flexed position and 45 reps in the extended position, the total daily number of reps was 180. At the start, the exercises were performed with body weight. Participants could progress by adding the 5, 10 and 15 kg, if they met the criteria. The criteria for adding weight was at least one week of training at the same weight and no disabling pain during or after the exercise during the week.
Treatment:
Other: Alfredson protocol
Silbernagel group (B)
Active Comparator group
Description:
Participants allocated to the Silbernagel exercise program were instructed to exercise every day with exception of the first week (every other day) for 12 months. The protocol contained 4 phases, which were based on a variety of CR exercises. The protocol contained concentric and eccentric CR on both legs, CR on one leg, CR in sitting, CR on the step, CR without step, quick rebound CR, CR with added weight and hops on the forefoot. The daily number of reps for 1st phase was 135, for the 2nd phase was 240, for the 3rd phase was 255 and for the 4th phase was 150. It's performed with body weight, added weight and plyometric loading progressively through all phases (maximal added weight is 15 kilos). To progress to the next phase participant needs to reach pain intensity during and after exercise under 5 from the 10 on the visual analogue scale, morning stiffness should not increase as well as pain during the week.
Treatment:
Other: Silbernagel protocol

Trial contacts and locations

1

Loading...

Central trial contact

Kryštof Voleský, Mgr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems